Clinical Trial: First-In-Human (FIH), Single Ascending Dose (SAD) Study and Multiple Ascending Dose (MAD) Study of SP-101 Injection

U.S., Jan. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07334249) titled 'First-In-Human (FIH), Single Ascending Dose (SAD) Study and Multiple Ascending Dose (MAD) Study of SP-101 Injection' on Dec. 16, 2025.

Brief Summary: The goal of this First-In-Human (FIH) trial is to learn about safety, tolerability and pharmacokinetics of single and multiple ascending doses of SP-101 in healthy adult volunteers.

Study Start Date: Dec. 23, 2025

Study Type: INTERVENTIONAL

Condition: Major Depressive Disorder, Healthy Volunteer

Intervention: DRUG: SP-101 injection

SP-101 is non-competitive antagonist against NMDA receptor and is administered by intravenous infusion.

DRUG: Placebo

Participants will be randomly...